Dr. Andy Y. Wen joined the Division of Pediatric Critical Care Medicine at Stanford University School of Medicine as Clinical Associate Professor of Pediatrics in 2019. He received his B.A. degree in Molecular Biology & Biochemistry at Rutgers University, and his medical degree from Rutgers Robert Wood Johnson Medical School. He completed a Pediatrics Residency Training Program at the State University of New York Downstate Medical Center and a Pediatric Critical Care Medicine Fellowship Training Program at the University of California Los Angeles.

After briefly working for Kaiser Permanente Southern California Permanente Medical Group (2012-2014), Dr. Wen joined the Division of Pediatric Critical Care at NYU School of Medicine (2014-2019). He assumed the role of Bellevue Hospital PICU medical director (2015-2019) and helped to expand Bellevue's Pediatric Trauma Program and Pediatric Critical Care Transport Services for the New York City (NYC) public hospital system, NYC Health & Hospitals.

While at UCLA, Dr. Wen received a T32 Training Grant to perform research investigating the role of transcription factor CREB in innate immune function using a murine model for AML. At NYU, his research projects included analyzing transfusion practices in the PICU, quality improvement projects targeting patients at high risk for unplanned extubation, and an ongoing project to explore the utility of NIRS as an early predictor of seizure activity. Dr. Wen is an Associate Editor for Journal of Pediatric Intensive Care and has reviewed abstracts for PAS, SCCM, and AMIA. His educational efforts include teaching Pediatric Fundamental Critical Care Support (PFCCS) courses, helping develop a Pediatric Residency Simulation course curriculum, and helping develop a Point-of-Care Ultrasound course for critical care advanced practice providers.

At Stanford University School of Medicine, Dr. Wen is in charge of Regional Pediatric Critical Care Outreach with a goal to promote medical education and expand the Stanford Children’s Health network to include all sick children in need of high quality care. Dr. Wen provides clinical services at both John Muir Medical Center and Lucile Packard Children’s Hospital.

Clinical Focus

  • Pediatrics
  • Pediatric Critical Care
  • Respiratory Failure
  • Heart Failure
  • COVID-19

Academic Appointments

Professional Education

  • Board Certification: American Board of Pediatrics, Pediatric Critical Care Medicine (2014)
  • Fellowship: UCLA Pediatric Critical Care Medicine Fellowship (2012) CA
  • Board Certification: American Board of Pediatrics, Pediatrics (2009)
  • Residency: SUNY Downstate Medical Center Pediatric Residency (2009) NY
  • Medical Education: Rutgers Robert Wood Johnson Medical School (2006) NJ

All Publications

  • Coronavirus Disease 2019-Associated PICU Admissions: A Report From the Society of Critical Care Medicine Discovery Network Viral Infection and Respiratory Illness Universal Study Registry. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies Tripathi, S., Gist, K. M., Bjornstad, E. C., Kashyap, R., Boman, K., Chiotos, K., Gharpure, V. P., Dapul, H., Sayed, I. A., Kuehne, J., Heneghan, J. A., Gupta, M., Khandhar, P. B., Menon, S., Gupta, N., Kumar, V. K., Retford, L., Zimmerman, J., Bhalala, U. S. 2021; 22 (7): 603-615


    To compare clinical characteristics and outcomes of children admitted to the PICU for severe acute respiratory syndrome coronavirus 2-related illness with or without multisystem inflammatory syndrome in children. The secondary objective was to identify explanatory factors associated with outcome of critical illness defined by a composite index of in-hospital mortality and organ system support requirement.Retrospective cohort study.Thirty-eight PICUs within the Viral Infection and Respiratory Illness Universal Study registry from March 2020 to January 2021.Children less than 18 years with severe acute respiratory syndrome coronavirus 2-related illness with or without multisystem inflammatory syndrome in children.Of 394 patients, 171 (43.4%) had multisystem inflammatory syndrome in children. Children with multisystem inflammatory syndrome in children were more likely younger (2-12 yr vs adolescents; p < 0.01), Black (35.6% vs 21.9%; p < 0.01), present with fever/abdominal pain than cough/dyspnea (p < 0.01), and less likely to have comorbidities (33.3% vs 61.9%; p < 0.01) compared with those without multisystem inflammatory syndrome in children. Inflammatory marker levels, use of inotropes/vasopressors, corticosteroids, and anticoagulants were higher in multisystem inflammatory syndrome in children patients (p < 0.01). Overall mortality was 3.8% (15/394), with no difference in the two groups. Diagnosis of multisystem inflammatory syndrome in children was associated with longer duration of hospitalization as compared to nonmultisystem inflammatory syndrome in children (7.5 d[interquartile range, 5-11] vs 5.3 d [interquartile range, 3-11 d]; p < 0.01). Critical illness occurred in 164 patients (41.6%) and was more common in patients with multisystem inflammatory syndrome in children compared with those without (55.6% vs 30.9%; p < 0.01). Multivariable analysis failed to show an association between critical illness and age, race, sex, greater than or equal to three signs and symptoms, or greater than or equal to two comorbidities among the multisystem inflammatory syndrome in children cohort. Among nonmultisystem inflammatory syndrome in children patients, the presence of greater than or equal to two comorbidities was associated with greater odds of critical illness (odds ratio 2.95 [95% CI, 1.61-5.40]; p < 0.01).This study delineates significant clinically relevant differences in presentation, explanatory factors, and outcomes among children admitted to PICU with severe acute respiratory syndrome coronavirus 2-related illness stratified by multisystem inflammatory syndrome in children.

    View details for DOI 10.1097/PCC.0000000000002760

    View details for PubMedID 33965987

    View details for PubMedCentralID PMC8240492

  • Effect of platelet storage duration on clinical outcomes and incremental platelet change in critically ill children TRANSFUSION Nellis, M. E., Spinella, P. C., Tucci, M., Stanworth, S. J., Steiner, M. E., Cushing, M. M., Davis, P. J., Karam, O. 2020; 60 (12): 2849-2858


    The safety of platelet (PLT) concentrates with longer storage duration has been questioned due to biochemical and functional changes that occur during blood collection and storage. Some studies have suggested that transfusion efficacy is decreased and immune system dysfunction is worsened with increased storage age. We sought to describe the effect of PLT storage age on laboratory and clinical outcomes in critically ill children receiving PLT transfusions.We performed a secondary analysis of a prospective, observational point-prevalence study. Children (3 days to 16 years of age) from 82 pediatric intensive care units in 16 countries were enrolled if they received a PLT transfusion during one of the predefined screening weeks. Outcomes (including PLT count increments, organ dysfunction, and transfusion reactions) were evaluated by PLT storage age.Data from 497 patients were analyzed. The age of the PLT transfusions ranged from 1 to 7 days but the majority were 4 (24%) or 5 (36%) days of age. Nearly two-thirds of PLT concentrates were transfused to prevent bleeding. The indication for transfusion did not differ between storage age groups (P = .610). After patient and product variables were adjusted for, there was no association between storage age and incremental change in total PLT count or organ dysfunction scoring. A significant association between fresher storage age and febrile transfusion reactions (P = .002) was observed.The results in a large, diverse cohort of critically ill children raise questions about the impact of storage age on transfusion and clinical outcomes which require further prospective evaluation.

    View details for DOI 10.1111/trf.16094

    View details for Web of Science ID 000571461200001

    View details for PubMedID 32959409

    View details for PubMedCentralID PMC8396066

  • Injuries associated with electric-powered bikes and scooters: analysis of US consumer product data. Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention DiMaggio, C. J., Bukur, M., Wall, S. P., Frangos, S. G., Wen, A. Y. 2019


    BACKGROUND: Powered, two-wheeled transportation devices like electric bicycles (E-bikes) and scooters are increasingly popular, but little is known about their relative injury risk compared to pedal operated bicycles.METHODS: Descriptive and comparative analysis of injury patterns and trends associated with E-bikes, powered scooters and pedal bicycles from 2000 to 2017 using the US National Electronic Injury Surveillance System.RESULTS: While persons injured using E-bikes were more likely to suffer internal injuries (17.1%; 95%CI 5.6 to 28.6) and require hospital admission (OR=2.8, 95%CI 1.3 to 6.1), powered scooter injuries were nearly three times more likely to result in a diagnosis of concussion (3% of scooter injuries vs 0.5% of E-bike injuries). E-bike-related injuries were also more than three times more likely to involve a collision with a pedestrian than either pedal bicycles (OR=3.3, 95% CI 0.5 to 23.6) or powered scooters (OR=3.3, 95% CI 0.3 to 32.9), but there was no evidence that powered scooters were more likely than bicycles to be involved in a collision with a pedestrian (OR=1.0, 95%CI 0.3 to 3.1). While population-based rates of pedal bicycle-related injuries have been decreasing, particularly among children, reported E-bike injuries have been increasing dramatically particularly among older persons.CONCLUSIONS: E-bike and powered scooter use and injury patterns differ from more traditional pedal operated bicycles. Efforts to address injury prevention and control are warranted, and further studies examining demographics and hospital resource utilisation are necessary.

    View details for DOI 10.1136/injuryprev-2019-043418

    View details for PubMedID 31712276

  • International Study of the Epidemiology of Platelet Transfusions in Critically Ill Children With an Underlying Oncologic Diagnosis PEDIATRIC CRITICAL CARE MEDICINE Nellis, M. E., Goel, R., Karam, O., Cushing, M. M., Davis, P. J., Steiner, M. E., Tucci, M., Stanworth, S. J., Spinella, P. C., Butt, W., Delzoppo, C., Erickson, S., Croston, E., Barr, S., Cavazzoni, E., de Jaeger, A., Tucci, M., French, M., Ropars, M., Clayton, L., Murthy, S., Krahn, G., Qu, D., Hui, Y., Johansen, M., Jensen, A., Jarnvig, I., Strange, D., Jayashree, M., Reddy, M., Sankar, J., Kumar, U., Lodha, R., Lerner, R., Paret, G., Schiller, O., Shostak, E., Dagan, O., Cavari, Y., Chiusolo, F., Cillis, A., Camporesi, A., Kneyber, M., Cochius-den Otter, S., Van Hemeldonck, E., Beca, J., Sherring, C., Rea, M., Abadesso, C., Moniz, M., Alshehri, S., Lopez-Herce, J., Ortiz, I., Garcia, M., Jordan, I., Flores Gonzalez, J., Perez-Ferrer, A., Pascual-Albitre, A., Grazioli, S., Doell, C., Davis, P. J., Curro, I., Jones, A., Peters, M. J., Lillie, J., Wellman, P. A., Aramburo, A., Shabana, M., Ramachandran, P., Sampaio, H., Sadasivam, K., Prince, N. J., Kanthimathinathan, H., Branco, R., Sykes, K. L., Mellish, C., Sarfatti, A., Weitz, J., Sanders, R. C., Hefley, G., Morzov, R. P., Markovitz, B., Ratiu, A., Sapru, A., Cowl, A. S., Faustino, E. S., Mahadevaiah, S., Beltramo, F., Jeyapalan, A. S., Cousins, M. K., Stone, C., Fortenberry, J., Pinto, N. P., Rodgers, C., Kniola, A., Porter, M., Owen, E., Lee, K., Thomas, L. J., Bembea, M. M., Awojoodu, R., Kelly, D., Hughes, K., Mansoor, Z., Pineda, C., Yager, P. H., Clark, M., Bateman, S. T., Kuo, K. W., Carlton, E. F., Boville, B., Leimanis, M., Steiner, M. E., Nerheim, D., Remy, K. E., Langford, L., Schicker, M., Singleton, M. N., Jarvis, J., Nett, S. T., Gertz, S., Killinger, J. S., Sturhahn, M., Parker, M. M., Harwayne-Gidansky, I., Watkins, L. A., Cassel, G., Aran, A., Kaushik, S., Wen, A. Y., Hassinger, A. B., Ozment, C. P., Ray, C. M., McCrory, M. C., Bass, A. L., Bigham, M. T., Anthony, H., Muszynski, J. A., Popelka, J., Fitzgerald, J. C., Leonard, S., Thomas, N. J., Spear, D., Marvin, W. E., Saini, A., McArthur, J., Norris, A., Ghafoor, S., Anderson, A., Monjure, T., Bysani, K., Christie, L. M., Loftis, L. L., Meyer, A. D., Tragus, R., Dibrell, H., Rupert, D., Delgado-Corcoran, C., Bodily, S., Willson, D., Dervan, L. A., Hanson, S. J., Hagen, S. A., Al-Subu, A. M., Pediat Acute Lung Injury Sepsis In, Pediat Critical Care Blood Res Net, Point Prevalence Study Platelet Tr 2019; 20 (7): E342–E351


    To describe the epidemiology of platelet transfusions in critically ill children with an underlying oncologic diagnosis and to examine effects of prophylactic versus therapeutic transfusions.Subgroup analysis of a prospective, observational study.Eighty-two PICUs in 16 countries.All children (3 d to 16 yr old) who received a platelet transfusion during one of the six predefined screening weeks and had received chemotherapy in the previous 6 months or had undergone hematopoietic stem cell transplantation in the last year.None.Of the 548 patients enrolled in the parent study, 237 (43%) had an underlying oncologic diagnosis. In this population, 71% (168/237) of transfusions were given prophylactically, and 59% (139/237) of transfusions were given at a total platelet count greater than 20 × 10/L, higher than the current recommendations. Those with an underlying oncologic diagnosis were significantly older, and received less support including less mechanical ventilation, fewer medications that affect platelet function, and less use of extracorporeal life support than those without an underlying oncologic diagnosis. In this subpopulation, there were no statistically significant differences in median (interquartile range) platelet transfusion thresholds when comparing bleeding or nonbleeding patients (50 × 10/L [10-50 × 10/L] and 30 × 10/L [10-50 × 10/L], respectively [p = 0.166]). The median (interquartile range) interval transfusion increment in children with an underlying oncologic diagnosis was 17 × 10/L (6-52 × 10/L). The presence of an underlying oncologic diagnosis was associated with a poor platelet increment response to platelet transfusion in this cohort (adjusted odds ratio, 0.46; 95% CI, 0.22-0.95; p = 0.035).Children with an underlying oncologic diagnosis receive nearly half of platelet transfusions prescribed by pediatric intensivists. Over half of these transfusions are prescribed at total platelet count greater than current recommendations. Studies must be done to clarify appropriate indications for platelet transfusions in this vulnerable population.

    View details for DOI 10.1097/PCC.0000000000001987

    View details for Web of Science ID 000476767300007

    View details for PubMedID 31107379

  • Effects of ABO Matching of Platelet Transfusions in Critically Ill Children. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies Nellis, M. E., Goel, R. n., Karam, O. n., Cushing, M. M., Davis, P. J., Steiner, M. E., Tucci, M. n., Stanworth, S. J., Spinella, P. C. 2019; 20 (2): e61–e69


    To determine if transfusing ABO compatible platelets has a greater effect on incremental change in platelet count as compared to ABO incompatible platelets in critically ill children.Secondary analysis of a prospective, observational study. Transfusions were classified as either ABO compatible, major incompatibility, or minor incompatibility. The primary outcome was the incremental change in platelet count. Transfusion reactions were analyzed as a secondary outcome.Eighty-two PICUs in 16 countries.Children (3 d to 16 yr old) were enrolled if they received a platelet transfusion during one of the predefined screening weeks.None.Five-hundred three children were enrolled and had complete ABO information for both donor and recipient, as well as laboratory data. Three-hundred forty-two (68%) received ABO-identical platelets, 133 (26%) received platelets with major incompatibility, and 28 (6%) received platelets with minor incompatibility. Age, weight, proportion with mechanical ventilation or underlying oncologic diagnosis did not differ between the groups. After adjustment for transfusion dose, there was no difference in the incremental change in platelet count between the groups; the median (interquartile range) change for ABO-identical transfusions was 28 × 10 cells/L (8-68 × 10 cells/L), for transfusions with major incompatibility 26 × 10 cells/L (7-74 × 10 cells/L), and for transfusions with minor incompatibility 54 × 10 cells/L (14-81 × 10 cells/L) (p = 0.37). No differences in count increment between the groups were noted for bleeding (p = 0.92) and nonbleeding patients (p = 0.29). There were also no differences observed between the groups for any transfusion reaction (p = 0.07).No differences were seen in the incremental change in platelet count nor in transfusion reactions when comparing major ABO incompatible platelet transfusions with ABO compatible transfusions in a large study of critically ill children. Studies in larger, prospectively enrolled cohorts should be performed to validate whether ABO matching for platelet transfusions in critically ill children is necessary.

    View details for DOI 10.1097/PCC.0000000000001779

    View details for PubMedID 30422914

  • Vaping-associated lung injury caused by inhalation of cannabis oil. Pediatric pulmonology Abeles, M. n., Popofsky, S. n., Wen, A. n., Valsamis, C. n., Webb, A. n., Halaby, C. n., Pirzada, M. n. 2019


    Vaping is a growing concern in adolescents, and a growing proportion is using electronic devices to inhale cannabis oil. The short-term and long-term effects of cannabis oil inhalation are not well understood. We report on a case of severe acute lung injury secondary to inhalation of cannabis oil via a vape pen, and propose a new term that describes lung injury related to vaping.

    View details for DOI 10.1002/ppul.24579

    View details for PubMedID 31746559

  • Platelet Transfusion Practices in Critically Ill Children. Critical care medicine Nellis, M. E., Karam, O. n., Mauer, E. n., Cushing, M. M., Davis, P. J., Steiner, M. E., Tucci, M. n., Stanworth, S. J., Spinella, P. C. 2018; 46 (8): 1309–17


    Little is known about platelet transfusions in pediatric critical illness. We sought to describe the epidemiology, indications, and outcomes of platelet transfusions among critically ill children.Prospective cohort study.Multicenter (82 PICUs), international (16 countries) from September 2016 to April 2017.Children ages 3 days to 16 years prescribed a platelet transfusion in the ICU during screening days.None.Over 6 weeks, 16,934 patients were eligible, and 559 received at least one platelet transfusion (prevalence, 3.3%). The indications for transfusion included prophylaxis (67%), minor bleeding (21%), and major bleeding (12%). Thirty-four percent of prophylactic platelet transfusions were prescribed when the platelet count was greater than or equal to 50 × 10 cells/L. The median (interquartile range) change in platelet count post transfusion was 48 × 10 cells/L (17-82 × 10 cells/L) for major bleeding, 42 × 10 cells/L (16-80 × 10 cells/L) for prophylactic transfusions to meet a defined threshold, 38 × 10 cells/L (17-72 × 10 cells/L) for minor bleeding, and 25 × 10 cells/L (10-47 × 10 cells/L) for prophylaxis in patients at risk of bleeding from a device. Overall ICU mortality was 25% but varied from 18% to 35% based on indication for transfusion. Upon adjusted analysis, total administered platelet dose was independently associated with increased ICU mortality (odds ratio for each additional 1 mL/kg platelets transfused, 1.002; 95% CI, 1.001-1.003; p = 0.005).The majority of platelet transfusions are given as prophylaxis to nonbleeding children, and significant variation in platelet thresholds exists. Studies are needed to clarify appropriate indications, with focus on prophylactic transfusions.

    View details for DOI 10.1097/CCM.0000000000003192

    View details for PubMedID 29727368

  • A 15-Year-Old with Aphasia and Right Hemiparesis. Journal of pediatric intensive care Wadowski, B. n., Chadha, T. n., Wen, A. Y. 2017; 6 (3): 221–24


    Takayasu arteritis (TA) is the third most common vasculitis in childhood, peaking in the second to third decades of life but affecting patients as young as 6 months of age. It often presents with nonspecific systemic symptoms, although at late stages, it may present with cardiac, renal, or focal neurologic sequelae of vascular compromise. In this case, we describe a 15-year-old patient who presented acutely with stroke. In the absence of more classic rheumatological symptoms and significant laboratory abnormalities on initial testing, the diagnosis of TA was only reached through extensive vascular imaging following consultation with multiple subspecialty teams. This case demonstrates the need to maintain a high index of suspicion for vasculitis in pediatric patients presenting with new onset stroke in the absence of known predisposing factors. Doing so may reduce the time to diagnosis, hasten treatment, and optimize outcomes.

    View details for DOI 10.1055/s-0037-1598205

    View details for PubMedID 31073452

    View details for PubMedCentralID PMC6260307

  • Increased Abscess Formation and Defective Chemokine Regulation in CREB Transgenic Mice PLOS ONE Wen, A. Y., Landaw, E. M., Ochoa, R., Cho, M., Chao, A., Lawson, G., Sakamoto, K. M. 2013; 8 (2)


    Cyclic AMP-response element-binding protein (CREB) is a transcription factor implicated in growth factor-dependent cell proliferation and survival, glucose homeostasis, spermatogenesis, circadian rhythms, and synaptic plasticity associated with memory. To study the phenotype of CREB overexpression in vivo, we generated CREB transgenic (TG) mice in which a myeloid specific hMRP8 promoter drives CREB expression. CREB TG mice developed spontaneous skin abscesses more frequently than wild type (WT) mice. To understand the role of CREB in myeloid function and innate immunity, chemokine expression in bone marrow derived macrophages (BMDMs) from CREB TG mice were compared with BMDMs from WT mice. Our results demonstrated decreased Keratinocyte-derived cytokine (KC) in CREB TG BMDMs but not TNFα protein production in response to lipid A (LPA). In addition, mRNA expression of KC and IL-1β (Interleukin)-1β was decreased in CREB TG BMDMs; however, there was no difference in the mRNA expression of TNFα, MCP-1, IL-6 and IL-12p40. The mRNA expression of IL-1RA and IL-10 was decreased in response to LPA. Nuclear factor kappa B (NFκB) expression and a subset of its target genes were upregulated in CREB TG mouse BMDMs. Although neutrophil migration was the same in both CREB TG and WT mice, Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity was significantly increased in neutrophils from CREB TG mice. Taken together, CREB overexpression in myeloid cells results in increased abscess formation in vivo and aberrant cytokine and chemokine response, and neutrophil function in vitro.

    View details for DOI 10.1371/journal.pone.0055866

    View details for Web of Science ID 000315153400169

    View details for PubMedID 23405224

    View details for PubMedCentralID PMC3566130

  • Chryseomonas luteola bloodstream infection in a pediatric patient with pulmonary arterial hypertension receiving intravenous treprostinil therapy. Infection Wen, A. Y., Weiss, I. K., Kelly, R. B. 2013; 41 (3): 719–22


    Treprostinil is a prostacyclin analogue approved for the treatment of pulmonary arterial hypertension (PAH). It is commonly administered through a central venous catheter (CVC). Treprostinil is associated with the incidence of Gram-negative bacterial bloodstream infections (BSI), a susceptibility that has been associated with a diluent used for treprostinil. We report the case of a 14-year-old boy with idiopathic PAH on continuous intravenous treprostinil therapy who presented with fever and fatigue. A blood culture drawn from his CVC was positive for the rare Gram-negative organism Chryseomonas luteola. The patient made a complete recovery with antibacterial treatment. This is the only documented case of a C. luteola BSI in a PAH patient receiving continuous intravenous treprostinil. We recommend maintaining a high index of suspicion for both common and rare Gram-negative pathogens and the early administration of appropriate antibiotic therapy in this population. The use of an alternate diluent solution, such as Sterile Diluent for Flolan, further decreases the infection risk.

    View details for DOI 10.1007/s15010-012-0399-2

    View details for PubMedID 23329255

  • The Role of the Transcription Factor CREB in Immune Function JOURNAL OF IMMUNOLOGY Wen, A. Y., Sakamoto, K. M., Miller, L. S. 2010; 185 (11): 6413-6419


    CREB is a transcription factor that regulates diverse cellular responses, including proliferation, survival, and differentiation. CREB is induced by a variety of growth factors and inflammatory signals and subsequently mediates the transcription of genes containing a cAMP-responsive element. Several immune-related genes possess this cAMP-responsive element, including IL-2, IL-6, IL-10, and TNF-α. In addition, phosphorylated CREB has been proposed to directly inhibit NF-κB activation by blocking the binding of CREB binding protein to the NF-κB complex, thereby limiting proinflammatory responses. CREB also induces an antiapoptotic survival signal in monocytes and macrophages. In T and B cells, CREB activation promotes proliferation and survival and differentially regulates Th1, Th2, and Th17 responses. Finally, CREB activation is required for the generation and maintenance of regulatory T cells. This review summarizes current advances involving CREB in immune function--a role that is continually being defined.

    View details for DOI 10.4049/jimmunol.1001829

    View details for Web of Science ID 000284311500004

    View details for PubMedID 21084670